QURE should continue climbing with recent sell off from news wall street did not like regarding licensing of their hemophilia drug. Support on Weekly MA found, MACD cross and RSI bullish divergence.
Phase 3 results should likely come out sometime in the future, like this quarter(?), based on company's prior reports.
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.